Drug profile · INN
ibrutinib
IMBRUVICA
ibrutinib (IMBRUVICA) is a tyrosine-protein kinase btk inhibitor. Associated with Janssen-Cilag Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — ibrutinib
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- ORAL
- Patents
- 1
- Programs
- 36
- Data quality
- 0.89
Quick answer
ibrutinib (IMBRUVICA) is a tyrosine-protein kinase btk inhibitor. Associated with Janssen-Cilag Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Tyrosine-protein kinase BTK inhibitor
Primary target: Tyrosine-protein kinase BTK
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| PMDA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is ibrutinib?
ibrutinib (IMBRUVICA) is a tyrosine-protein kinase btk inhibitor. Associated with Janssen-Cilag Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for ibrutinib?
IMBRUVICA is a marketed brand name for ibrutinib. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ibrutinib?
ibrutinib has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.